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ABSTRACT 
Photodynamic therapy (PDT) utilizes the combined interaction of a photosensitizer, light and 
molecular oxygen to ablate tumor tissue.  Maximizing the accumulation of the photosensitizer 
protoporphyrin IX (PpIX) within different cell types would be clinically useful.  Dermatological 
PpIX-induced PDT regimes produce good clinical outcomes but this currently only applies when 
the lesion remains superficial.  Also, as an adjuvant therapy for the treatment of primary brain 
tumors, fluorescence guided resection (FGR) and PDT can be used to highlight and destroy 
tumor cells unreachable by surgical resection.  By employing iron chelators PpIX accumulation 
can be enhanced.  Two iron chelating agents, 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride 
(CP94) and dexrazoxane, were individually combined with the porphyrin precursors 
aminolevulinic acid (ALA), methyl aminolevulinate (MAL) and hexyl aminolevulinate (HAL).  
Efficacies of the iron chelating agents were compared by recording the PpIX fluorescence in 
human squamous epithelial carcinoma cells (A431) and human glioma cells (U-87 MG) every 
hour for up to 6 hours.  Coincubation of ALA/MAL/HAL with CP94 resulted in a greater 
accumulation of PpIX compared to that produced by coincubation of these congeners with 
dexrazoxane.  Therefore the clinical employment of iron chelation, particularly with CP94 could 
potentially increase and/or accelerate the accumulation of ALA/MAL/HAL-induced PpIX for 
PDT or FGR.   
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INTRODUCTION 
Photodynamic therapy (PDT) is a clinical treatment resulting from the interaction of a 
photosensitizer, molecular oxygen and light of a specific wavelength.  When all three 
components are combined simultaneously in sufficient amounts they result in the production of 
singlet oxygen and other free radicals causing diseased cells to undergo cell death through 
necrosis or apoptosis (1).  An increased or excessive amount of photosensitizer would be 
clinically useful and so research is taking place to try to increase photosensitizer accumulation 
during PDT with a view to ultimately enhancing clinical efficacy.  
The prodrugs aminolevulinic acid (ALA), methyl aminolevulinate (MAL) and hexyl 
aminolevulinate (HAL) are porphyrin-inducing precursors of the endogenous photosensitizer 
protoporphyrin IX (PpIX) produced via the heme biosynthesis pathway in nucleated cells in 
humans.  Usually in cells, following PpIX production the next stage in the pathway is the 
insertion of ferrous iron (Fe2+) under the action of the ferrochelatase enzyme (2), to convert PpIX 
into heme, with the presence of free heme acting as a negative feedback mechanism limiting the 
production of any further ALA (3).  However, the exogenous introduction of large amounts of 
ALA/MAL/HAL bypasses this negative feedback loop and there is a resultant accumulation of 
heme and heme precursors in the cell.  Notably, the conversion of PpIX to heme by 
ferrochelatase is relatively slow which causes PpIX to temporarily accumulate within cells (4).  
In addition, in diseased cells some enzymes within the heme biosynthesis pathway are over or 
under expressed favoring the continual production of PpIX (5-7).   
  The first results from a clinical trial utilizing ALA-induced PpIX photodynamic therapy 
were reported just over 20 years ago (8) and since then PpIX-induced PDT for a variety of 
cancers has been investigated.  Topically it can be used for the treatment of a number of 
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dermatological indications including the most common form of skin cancer, basal cell carcinoma 
(BCC).  Although PpIX-induced PDT produces good clinical outcomes and excellent cosmesis 
for the thinner, superficial BCCs (sBCC), efficacy for the treatment of thicker nodular BCCs 
(nBCC) remains lower than conventional surgical excision (9).  For patients presenting with 
nBCC lesions that are large, multiple and/or on cosmetically sensitive sites (10), surgical 
excision can be a disfiguring and distressing experience.  Therefore, enhancement of PpIX-
induced PDT for these thicker lesions would be beneficial. 
Another promising application of PpIX accumulation within cancer cells is within human 
brain tumor cells.  Human glioblastomas are aggressive primary brain tumors which remain the 
most common form of this malignancy (11) and problematic to treat given their infiltrative and 
mobile characteristics (12).  Conventional treatments for brain tumors include surgery, 
radiotherapy and chemotherapy.  Although these conventional therapies are potentially curative, 
the 5 year survival rates remain below 5%, with approximately 80% of reoccurrences occurring 
within 2 cm of the surgically resected margin (13).  Activated PpIX, under light of a specific 
wavelength, has the ability to fluoresce and in 1998 Stummer et al. observed a fluorescence ratio 
of 5:1 between malignant and normal tissue in vitro (14).  Utilizing a technique termed 
fluorescence guided resection (FGR) (15); surgeons can exploit PpIX’s natural fluorescent 
properties enabling greater precision in the removal of brain tumors (16, 17).  In addition to 
FGR, PpIX-induced PDT, as an adjuvant therapy, can be used to destroy residual tumor tissue 
unreachable by surgical resection.  Improvement of PpIX accumulation within glioblastoma cells 
for the application of FGR and/or PDT could potentially improve prognosis, prolong time 
interval to tumor recurrence and vitally improve quality of life.    
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It has been shown that PpIX accumulation can be enhanced by employing iron chelation 
(18).  An iron chelating agent can temporarily remove free Fe2+ from the system, inhibiting its 
insertion into PpIX, thus preventing the formation of heme and as a result PpIX accumulates in 
the cell (19).  Iron chelating agents which have been investigated in the past include 
ethylenediamine tetra acetic acid (EDTA) (20) and desferrioxamine (DFO) (21) Liu et al. (2004) 
(2) concluded that a non-specific metal chelator (with the potential to inhibit ferrochelatase 
activity), calcium-disodium edentate (CaNa2 EDTA) combined with ALA increased PpIX 
accumulation and photosensitization in Hep-2 cells.  In addition to cell culture tests they treated 
12 non-melanoma skin cancer patients with ALA combined with CaNa2 EDTA-PDT and found 
greater depth of penetration than compared to ALA-PDT alone.  From these experiments they 
postulated that if CaNa2 EDTA combined with ALA was used clinically for the treatment of 
cutaneous cancers the depth of PpIX penetration and therefore clinical outcome could be 
improved (2).  DFO has greater specificity for iron than EDTA and research by our group has 
shown 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) to be significantly superior to 
DFO in the enhancement of PpIX accumulation using ALA and MAL in fetal lung fibroblasts 
and squamous carcinoma cells (19). 
Dexrazoxane (ICRF-187) is a clinically approved anthracycline-induced cardioprotective 
agent which has been used for more than 20 years (22).  Dexrazoxane’s proposed mechanism of 
action is that it readily penetrates cell membranes, is intracellularly converted into two one-ring 
open intermediates followed by the production of ADR-925, which can either remove iron from 
the iron-anthracycline complex or bind to free iron (22).  It has been reported that all three 
hydrolysis products are good iron-chelating agents (23) and dexrazoxane itself is therefore 
known as an iron chelating prodrug.     
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These findings suggest that dexrazoxane may be used clinically as a successful iron 
chelating prodrug to enhance PpIX accumulation and to our knowledge has not previously been 
investigated for this purpose.  This study therefore compares the effects of the iron chelating 
agents CP94 and dexrazoxane, on the accumulation of PpIX within human squamous epithelial 
cells and human glioma cells in vitro with ALA, MAL and HAL as the porphyrin precursors.   
 
 
MATERIALS AND METHODS 
Chemicals and cells 
All reagents and chemicals were purchased from Sigma-Aldrich Chemical Company (Poole, 
UK) unless otherwise stated. U-87 MG (human glioblastoma-astrocytoma, epithelial-like) and 
A431 (human epithelial squamous carcinoma) cells were purchased from the European 
Collection of Cell Cultures (ECACC, Wiltsure, UK).  Under aseptic conditions in a class II 
laminar flow cabinet, cells were cultured in Eagle’s minimum essential medium (EMEM) with 
10% fetal calf serum (FCS, standardized to give an iron concentration between 450 and 600 
µg/100 g), 2% (200 mM) L-glutamine and 2% (200 U mL-1) penicillin and (200 µg mL-1) 
streptomycin solution.  Stock solutions of ALA/MAL/HAL were prepared in phosphate buffered 
saline (PBS), adjusted to physiological pH (pH 7.4) using NaOH (0.5 mM), filter sterilized (0.22 
µm Millipore) and stored at -20ºC for up to one month.  Cells were grown in 5% CO2 at 37ºC 
and left to grow until 70% confluent at which time cells were routinely passaged (every 3-5 
days).   
 
Iron chelator cytotoxicity 
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Before investigating PpIX accumulation the dark toxicity of each iron chelating agent was 
determined using the XTT (2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazololium-5-
carboxyanilide inner salt) cell viability assay.  This is a colorimetric assay based on the reduction 
of the XTT tetrazolium salt by mitochondrial dehydrogenase enzymes.   
A431 and U-87 MG cells were seeded into multiwell plates at a density of 1 x 105 cells 
per mL (1 x 104 cells per well) and left to adhere overnight at 5% CO2 and 37ºC.  Under low 
light conditions the medium was aspirated from the wells and the cells washed with PBS in 
preparation for the addition of freshly prepared test solutions.  Final concentrations of 
dexrazoxane and CP94 were prepared with modified EMEM (minus phenol red): dexrazoxane 
(50 and 150 µm) and CP94 (150 µm).  A 100 µl volume of each test solution was added to the 
cells in triplicate wells.  Control wells were also included which contained cells only incubated 
with modified EMEM.  Once the test solutions had been added, cells were incubated for 3 hours 
in 5% CO2 at 37ºC. 
 Following this incubation period, the medium containing the test solutions was removed 
from the wells and cells were washed three times with PBS.   A volume of 120 µl serum free 
medium per well containing XTT was then added.   The plate was returned to the incubator for a 
further 2 hours and following this, absorbance of the resulting color change was measured with a 
Synergy HT plate reader (BIO-TEK, Germany).  Absorbance was read at 450 nm and 690 nm, 
with the 690 nm wavelength being used as a reference range and subtracted from the 450 nm 
reading.  Measurements were represented as a percentage of the control cells, incubated with 
modified EMEM only.   
 
PpIX fluorescence quantification 
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Cells were seeded into multiwell plates at a density of 1 x 105 cells per mL (1 x 104 cells per 
well) and left to adhere overnight at 5% CO2 and 37ºC.  Under low light conditions the medium 
was aspirated from the wells and the cells washed with PBS in preparation for the addition of 
freshly prepared test solutions.  Final concentrations of ALA/MAL/HAL were prepared with 
modified EMEM (minus phenol red): ALA (250 µm) / MAL (1000 µm) / HAL (10 µm).  To 
produce solutions of equal iron binding equivalence dexrazoxane was used at 50 µM and CP94 
at a concentration of 150 µM.  To compare equal molar concentrations dexrazoxane was also 
used at 150 µM.  All concentration combinations were tested in quintuplicate on each plate in a 
minimum of three separate experiments conducted on separate days. 
 Under dark room conditions PpIX fluorescence quantification was conducted using a 
multi-well plate reader (Synergy HT, Bio-Tek, UK). Measurements were taken from the bottom 
of the wells with a 400 ± 30 nm excitation filter and a 645 ± 40 nm emission filter in place.  
Readings were taken every hour for a total of 6 hours and under dark room conditions to reduce 
photobleaching of PpIX.  After/between each reading, plates were kept in the dark at 5% CO2 
and 37ºC.   
 
Data analysis and statistics 
The PpIX fluorescence measurements from the control cells not incubated with any test 
compound were used to remove natural cellular PpIX autofluorescence from all the other 
measurements made from the same plate.  Following the determination of the presence of 
parametric data sets statistical significance between individual groups was determined using the 
Student’s t-test and ANOVA was employed when considering differences between data sets. 
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RESULTS 
Dark toxicity of CP94 and dexrazoxane  
The dark toxicity of the two iron chelating agents, CP94 and dexrazoxane, incubated alone with 
squamous carcinoma (A431) and glioma (U-87 MG) cells was investigated (Fig 1).  It was 
observed that both iron chelating agents produced  similar results in each cell type with the 
Student’s t-test revealing that at the concentrations tested no statistically significant toxicity was 
observed with either iron chelating agent, when compared to the same cell type incubated with 
modified EMEM alone (control group) (Fig 1). 
 
The effect of CP94 and dexrazoxane on PpIX accumulation in squamous carcinoma 
(A431) cells  
In the human epithelial carcinoma cells (A431) incubated with the prodrugs ALA/MAL/HAL 
with and without the iron chelators CP94 and dexrazoxane, PpIX fluorescence levels increased 
hourly and using an ANOVA with a post-test a significant linear trend was found (p<0.01, Figs 
2a–2b).  Comparison of ALA/MAL/HAL + CP94 with ALA/MAL/HAL alone (Figs 2a–2c) 
indicated that greater levels of PpIX fluorescence were detected in cells in the CP94 group and 
this difference was found to be statistically significant (ANOVA, p<0.05) with all three 
prodrugs. When cells incubated with ALA/MAL/HAL + dexrazoxane, at either concentration (50 
µM or 150 µM), were compared to those incubated with ALA/MAL/HAL alone (Figs 2a–2c) 
using ANOVA to detect any significant difference (p<0.05) none was found.  However, when 
using a Student’s t-test between the prodrugs alone and the prodrugs + 150 µM dexrazoxane data 
sets, statistical significance was observed for the ALA/MAL/HAL + 150 µM dexrazoxane 
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treated cells at 2 hr (Fig 2a) / 1 hr (Fig 2b) / 3 hr (Fig 2c) respectively, and at all time points 
thereafter (p<0.05).   
 Comparison of ALA/MAL/HAL + CP94 with ALA/MAL/HAL + dexrazoxane (Figs 2a–
2c) indicated that greater levels of PpIX fluorescence were detected in cells in the CP94 group 
and this difference was found to be statistically significant (ANOVA; with 50 µM dexrazoxane 
p<0.001, with 150 µM dexrazoxane p<0.01).  Further analysis found significant enhancement in 
the ALA/MAL + CP94 treated cells compared to ALA/MAL + 50 µM dexrazoxane treated cells 
at every time point (Student’s t-test, p<0.05; Figs 2a and 2b) and at a significance of p<0.05 
after the first hour between HAL + CP94 and HAL + 50 µM dexrazoxane (Fig 2c).  In addition, 
significant enhancement was observed between ALA/MAL/HAL + CP94 treated cells with 
ALA/MAL/HAL + 150 µM dexrazoxane for; ALA (p<0.05 at ≥ 1 hr), MAL (p<0.05 at ≥ 2 hr), 
HAL (p<0.05 at ≥ 0 hr). 
In the cells incubated with ALA/MAL +/- CP94 or dexrazoxane (Figs 2a and 2b) the 
natural levels of PpIX detected, although similar, were greater when incubated with MAL +/- 
CP94 or dexrazoxane, at every time point.  In the cells incubated with HAL alone and with HAL 
+ 50 µM dexrazoxane, the levels of PpIX fluorescence were observed to decrease following 5 
hours, whereas following 5 hours coincubation with HAL + CP94 or HAL + 150 µM 
dexrazoxane PpIX levels continued to increase (Fig 2c).  Furthermore, the PpIX levels observed 
with 10 µM HAL were not as great as those produced by 250 µM ALA or 1000 µM MAL.  
Although the control results and ALA/MAL/HAL + CP94 results were comparable with our 
previous findings (24). 
The enhanced levels of PpIX fluorescence detected could be represented as reduced 
incubation times (Fig 2d).  Comparable levels of fluorescence to the cells incubated with ALA 
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alone at 6 hours could be achieved in ~ 4 hr 40 min with ALA + 50 µM dexrazoxane, in just over 
3 hr with ALA + 150 µM dexrazoxane and in just over 2 hr with ALA + CP94 (approximately a 
third of the time required by ALA alone).  Similar reductions in incubation times were observed 
with the MAL treated cells.  Comparable levels of fluorescence to the cells incubated with MAL 
alone at 6 hours could be achieved in 5 hr with MAL + 50 µM dexrazoxane, in ~ 4 hr with MAL 
+ 150 µM dexrazoxane and in just over 2 hr with MAL + CP94.  Even greater reductions in 
incubation times were observed for the HAL treated cells.  Comparable levels of fluorescence to 
the cells incubated with HAL alone at 6 hours could be achieved in ~ 3 hr with HAL + 50 µM 
dexrazoxane, in ~ 2 hr 20 min with HAL + 150 µM dexrazoxane and in just over 1 hr with HAL 
+ CP94.  Although, notably less PpIX fluorescence was observed when A431 cells were 
incubated with 10 µM HAL alone compared to incubation with either 250 µM ALA or 1000 µM 
MAL alone.              
 
The effect of CP94 and dexrazoxane on PpIX accumulation in glioma (U-87 MG) 
cells 
In human glioma cells (U-87 MG) incubated with the prodrugs ALA/MAL/HAL with and 
without the iron chelating agents CP94 and dexrazoxane, PpIX fluorescence levels increased 
hourly (Figs 3a–3c) and produced greater levels of PpIX fluorescence than the A431 cells with 
or without the iron chelating agents (Figs 2a–2c).  For the U-87 MG cells, comparison of the 
prodrugs alone and the prodrugs with either iron chelating agent, using an ANOVA, revealed no 
statistically significant enhancement in PpIX fluorescence (p<0.05) trends (Figs 3a–3c).   
However, using a Student’s t-test to compare PpIX fluorescence levels in individual 
groups, when cells were treated with the prodrugs alone or the prodrugs with either iron chelator, 
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significant PpIX enhancements were found at specific time points.  In Fig 3a, cells treated with 
ALA + CP94 at every time point produced statistically greater PpIX fluorescence than the ALA 
only treated cells (p<0.05).  In addition, compared to treatment with ALA alone, cells treated 
with ALA + 50 µM dexrazoxane had statistically greater PpIX fluorescence between 5 and 6 hr 
and cells treated with ALA + 150 µM dexrazoxane had statistically greater PpIX fluorescence 
between 1–6 hr (p<0.05).  Compared to treatment with ALA + 50 µM dexrazoxane, cells 
incubated with ALA + CP94 produced higher levels of PpIX fluorescence at the majority of time 
points investigated, with the exception of 2 hr.  However, no statistically significant differences 
were observed between individual ALA + 150 µM CP94 or ALA + 150 µM dexrazoxane groups. 
In the cells incubated with MAL +/- CP94 or dexrazoxane (Fig 3b), the levels of PpIX, 
although visually consistently greater when combined with CP94 were only significantly 
different to the MAL only controls and those treated with 50 µM or 150 µM dexrazoxane at 0 
and 1 hr.  In the cells incubated with HAL alone and with HAL + 50 µM dexrazoxane levels of 
PpIX fluorescence were observed to decrease following 5 hours, whereas following 5 hours 
incubation with HAL + CP94 or HAL + 150 µM dexrazoxane PpIX levels continue to increase 
(Fig 3c).  In addition, following 4 hours plus incubation, levels of PpIX fluorescence were 
significantly greater when cells were incubated with HAL + 150 µM dexrazoxane compared to 
incubation with HAL + CP94 (p<0.05). 
The enhanced levels of PpIX fluorescence detected could again be represented as reduced 
incubation times (Fig 3d).  Comparable levels of fluorescence to the cells incubated with ALA 
alone at 6 hours could be achieved in ~ 4 hr 50 min with ALA + 50 µM dexrazoxane and in ~ 3 
hr 30 min with either ALA + 150 µM CP94 or dexrazoxane.  Following 6 hours incubation with 
MAL alone comparable levels of fluorescence were achieved at ~ 6 hr with MAL + 50 µM 
13 
 
dexrazoxane and in 5 hr 12 minutes with MAL + CP94.  However, comparable levels of 
fluorescence to the cells incubated with MAL alone at 6 hours were not reached with MAL + 
150 µM dexrazoxane. Greater reductions in incubation times were once again observed for the 
HAL treated cells.  Comparable levels of fluorescence to the cells incubated with HAL alone at 6 
hours could be achieved in ~ 3 hr 20 min with HAL + 50 µM dexrazoxane and in ~ 2 hr 40 min 
with either MAL + 150 µM CP94 or dexrazoxane.  These findings in human glioma cells (Fig 
3d) were therefore similar as those produced in human squamous epithelial carcinoma cells (Fig 
2d) when employing ALA or HAL as the prodrug but not as marked when using MAL.    
 
 
DISCUSSION 
One of the major limitations of PpIX-induced FGR and PDT is the accumulation and localization 
of PpIX within tumor cells.  Although it has been increasingly reported that PpIX accumulation 
can be enhanced with iron chelation (25), the use of which PpIX precursor and which iron 
chelating agent to administer for different cell types and which to take forward into clinical 
experimentation remains inconclusive.   
This in vitro study was carried out to compare the increase in PpIX fluorescence, over a 6 
hour time period, in human squamous epithelial carcinoma cells (A431) and human glioma cells 
(U-87 MG) after exogenous administration of ALA/MAL/HAL with and without the two iron 
chelating agents CP94 and dexrazoxane.  CP94 was used because previous in vitro studies have 
shown CP94 to be significantly superior to the well-known iron chelator DFO (21) at increasing 
levels of PpIX (19).  In addition, CP94 combined with ALA has been tested in vivo, with the 
PpIX fluorescence produced in rat colonic mucosa double that of ALA alone (25).  An ongoing 
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clinical investigation using increasing concentrations of CP94 combined with ALA or MAL to 
carry out PDT on nBCCs which after 6 weeks are surgically excised, is currently being 
undertaken.  Clinical assessment prior to excisions has so far demonstrated that using ALA + 
40% CP94 produced a significantly greater clearance rate in nBCCs than with ALA-PDT alone 
(26).  The clinical use of CP94 however remains experimental and non-licensed at the current 
time.  However, dexrazoxane is already approved and used clinically, exerting its iron chelating 
properties successfully as a protective agent for anthracycline-induced cardiotoxicity.  Therefore, 
comparing the iron chelating efficacies of CP94 and dexrazoxane with their ability to increase 
PpIX accumulation is useful, and to our knowledge this is the first study to investigate the 
combined interaction of any PpIX precursor with dexrazoxane.   
In the human squamous epithelial carcinoma cells (A431) both CP94 and dexrazoxane 
treatment groups increased PpIX fluorescence when combined with the three prodrugs 
ALA/MAL/HAL, compared to each prodrug alone and markedly, CP94 produced significantly 
greater levels of PpIX accumulation when compared to dexrazoxane for each of the prodrugs 
tested.  In addition, in A431 cells treated with CP94 and dexrazoxane, at both concentrations 
tested, the same amount of PpIX fluorescence normally produced during 6 hour incubation with 
ALA/MAL/HAL was produced within shorter time periods.  Notably, this level of fluorescence 
was reached 3 times quicker when ALA and MAL were combined with CP94 and 6 times 
quicker when HAL was combined with CP94.  Currently, dermatology PDT clinic drug-light-
interval times are 4-6 hours for ALA and 3 hours for MAL (27).  This time is important to allow 
for optimum levels of PpIX to accumulate and to produce an optimum ratio of photosensitizer 
accumulation between tumor and non tumor tissues (19).  The results from this study suggest 
dermatology PDT clinics may benefit most from inclusion of CP94 in their treatment regimes to 
15 
 
firstly reduce incubation times resulting in a greater number of treatments being feasible in a day 
and thus reduced waiting times for patients and secondly to increase efficacy in applications 
requiring enhancement.  However, use of the more clinically acceptable dexrazoxane may also 
produce some clinical benefits, and warrants further investigation. 
In A431 cells it has been demonstrated here that CP94 is a greater enhancer of PpIX 
accumulation than both concentrations of dexrazoxane investigated, for each of the PpIX 
precursors tested.  Notably, dexrazoxane was employed at two concentrations; 50 µM and 150 
µM, whereas CP94 was only employed at 150 µM.  This was done to take into account the 
different iron binding equivalences of the two iron chelating agents.  Dexrazoxane is hexadentate 
meaning a single Fe molecule is coordinated by one chelator molecule in a 1:1 ratio.  CP94 is 
bidentate meaning it binds iron in the ratio of 3:1.  As a result the concentrations employed were 
chosen to produce solutions of equal iron binding equivalence (150 µM CP94 vs 50 µM 
dexrazoxane) and fairly compared equimolar concentrations of each iron chelating agent (150 
µM) but in each case CP94 out performed dexrazoxane.   
 The end hydrolysis product of dexrazoxane, ADR-925 is a cyclic derivative of EDTA 
which has been investigated previously as an enhancer of PpIX-induced PDT (20).  The polar 
nature of ADR-925, like that of EDTA prevents it from being able to cross cell membranes but 
this obstacle is overcome when dexrazoxane is employed instead of EDTA as its likely mode of 
transport is passive diffusion across cell membranes, similar to that shown for ICRF-159 
(razoxane) (28).  As CP94 and dexrazoxane can both readily enter cells one could postulate the 
decreased efficacy of dexrazoxane to increase PpIX accumulation compared to CP94, might be 
explained by dexrazoxane’s conversion to its hydrolysis products.  Physiological conditions 
studies (29, 30) have demonstrated that dexrazoxane is hydrolyzed to its one-ring open 
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intermediates with a T1/2 of 9.3 hr at 37ºC and pH 7.4, whereas the final hydrolysis product 
ADR-925 was produced with a T1/2 of 23 hr.  In the present study incubation times of up to 6 
hours only were employed but PpIX accumulation was still observed to occur at a greater level 
when each PpIX precursor was combined with dexrazoxane than incubation with each PpIX 
precursor alone.  This could be explained by the observation that dexrazoxane can be 
enzymatically hydrolyzed, more rapidly, by dihydropyrimidine amidohydrolase (DHPase) to its 
one-ring open intermediates (31, 32), which like ADR-925 are also able to chelate iron.  In 
addition, nonenzymatic metal-ion-promoted hydrolysis of dexrazoxane has also been reported 
(23, 33) in which it was suggested that both ferrous and ferric forms of iron are able to promote 
the hydrolysis of dexrazoxane or its open ring intermediates enhancing their iron-chelating 
potential.              
In the human glioma cells (U-87 MG) it was again demonstrated that iron chelation with 
either agent significantly increased PpIX fluorescence when combined with the three prodrugs 
ALA/MAL/HAL, compared to each prodrug alone.  These results are complementary to previous 
work conducted by ourselves (24) and also by others (34) who have considered the use of PpIX-
induced FGR.  Valdes et al. (2010) (34) suggested that although the use of ALA for FGR has 
shown promising results in previous clinical trials, due to heterogeneous staining and variation in 
PpIX production some tumor margins go undetected, proposing this may be remedied by 
combining FGR with iron chelation.  In a recent study by Valdes et al. mice were implanted with 
xenograft U251-GFP Glioma tumor cells and administered with DFO once a day for 3 days prior 
to ALA administration producing a 50% increase in PpIX fluorescence relative to the control 
group (34).   
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Notably, in our study, at concentrations of equal binding equivalence (50 µM 
dexrazoxane vs 150 µM CP94) CP94 was a statistically greater enhancer of PpIX accumulation 
than dexrazoxane, when ALA or HAL were used as the PpIX precursor.  With the prodrug MAL 
however these differences were less marked.  However, at equimolar concentrations (150 µM) 
PpIX accumulation between the two iron chelating agents was similar, with the exception of 
coincubation with HAL where coincubation with dexrazoxane at 150 µM resulted in greater 
PpIX accumulation compared to coincubation of HAL with CP94.  Nevertheless, the same 
amount of PpIX fluorescence normally produced during 6 hour incubation with HAL alone was 
produced in less than 3 hours when HAL was combined with either CP94 or 150 µM 
dexrazoxane.  The in vitro results suggest that HAL coincubated with either iron chelator (CP94 
or dexrazoxane) would most likely be the most favorable PpIX-induced therapy for the treatment 
of primary gliomas through FGR and/or PDT.  However, unlike dermatology clinics where a 
reduced prodrug incubation period is highly favorable, in the surgical resection of brain tumors a 
reduced incubation period would take second place to producing the maximal amount of PpIX 
possible, given that successful tumor clearance is directly linked to the level of PpIX 
accumulated within malignant cells and is of major importance.   
In mice implanted with glioma tumour cells with subsequent administration of DFO and 
ALA, 50% more PpIX fluorescence was recently demonstrated, relative to the control group 
(34).  As previously mentioned CP94 has been shown to be significantly superior to DFO in 
enhancing PpIX accumulation (19) and CP94 has the ability to cross the blood-brain barrier 
(BBB) (35).  In vivo animal studies should therefore investigate the hypothesis that exogenous 
systemic administration of ALA/MAL/HAL with CP94 in malignant glioma tumours could 
significantly increase PpIX fluorescence.  In addition, tumour-to-normal tissue selectivity should 
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also be investigated in vivo.  In the surgical resection of brain tumours sparing normal tissue to 
maximize post-operational quality of life is an important consideration therefore achieving 
maximal tumour-to-normal PpIX selectivity is highly sought-after.  Dexrazoxane is hydrophilic 
and as a result has poor BBB penetration (36).  However, there is a vast (and very desirable) 
amount of research into assisting larger drug molecules to cross the BBB.  This research includes 
the co-administration of a bradykinin agonist which increases the permeability of the BBB 
allowing the drug of interest to pass into the brain compartment (37).  An increasingly popular 
area of research, nanotechnology, may also allow passage of drugs across the BBB and in 
addition specific brain tumour targeting (38).   
Our results in both cell types demonstrate coincubation with CP94 produces the greatest 
amount of PpIX fluorescence in the order MAL>ALA>HAL.  Markedly, U-87 MG cells 
produced much greater levels of PpIX fluorescence than the A431 cells with all three prodrugs.  
Cell types show variability in their PpIX accumulation probably due to differences in their 
ferrochelatase activity which varies between cell types (6, 39).  Ferrochelatase converts PpIX to 
heme by inserting a Fe2+ into the protoporphyrin ring.  Thus, although not investigated here, if 
U-87 MG cells have a lower activity of the ferrochelatase enzyme than A431 cells and a higher 
metabolic rate, this could explain why over the same incubation period U-87 MG cells produce 
greater levels of PpIX fluorescence.  
The objective of this study was to compare the effects of two iron chelating agents in 
combination with the porphyrin precursors ALA/MAL/HAL.  For both cell types coincubation 
with CP94 produced a greater enhancement of PpIX accumulation than coincubation with 
dexrazoxane although this difference was most marked in the dermatological cells employed.  
The greatest amount of PpIX fluorescence was observed in the order MAL>ALA>HAL and the 
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same amount of PpIX fluorescence normally produced during 6 hour incubation with each 
prodrug alone was produced in shorter incubation times, when coincubated with CP94, achieved 
in the order HAL<ALA<MAL.  In conclusion, although the enhancement of PpIX accumulation 
for different cell types may require different PpIX precursors or iron chelator combinations, this 
study has demonstrated that for ALA/MAL/HAL-induced PpIX production, enhancement can be 
successfully achieved with iron chelation and provides further evidence for the combined clinical 
investigation of this method of PDT/FGR enhancement.   
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FIGURE CAPTIONS 
 
Figure 1:  Dark toxicity of the test compounds, CP94 (150 µM) and dexrazoxane (50 & 150 
µM), incubated with A431 and U-87 MG cells alone.  Cell viability is presented as a percentage 
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of the blank control cells incubated with modified EMEM alone.  Bars indicate the mean of 3 
wells with 1 standard deviation.   
 
Figure 2:  PpIX fluorescence in A431 cells incubated with (a) 250 µM ALA, (b) 1000 µM 
MAL, (c) 10 µM HAL alone or in combination with CP94 (150 µM) or dexrazoxane (50 & 150 
µM), as a function of time. A statistical significant difference in PpIX fluorescence from the 
prodrug only incubated control cells is indicated by * (p<0.05).  A statistically significant 
difference between cells incubated with CP94 and 50 µM dexrazoxane is indicated by + 
(p<0.05) and a statistically significant difference between cells incubated with CP94 and 150 
µM dexrazoxane is indicated by ∆ (p<0.05).  Times for chelator incubated cells to achieve 
comparable levels of fluorescence to the ALA/MAL/HAL alone treated cells at 6 hr, indicated by 
the hashed lines on panels (a) – (c), are presented in (d).   
 
Figure 3:  PpIX fluorescence in U-87 MG cells incubated (a) 250 µM ALA, (b) 1000 µM MAL, 
(c) 10 µM HAL alone or in combination with CP94 (150 µM) or dexrazoxane (50 & 150 µM), as 
a function of time. A statistical significant difference in PpIX fluorescence from the prodrug only 
incubated control cells is indicated by * (p<0.05).  A statistically significant difference between 
cells incubated with CP94 and 50 µM dexrazoxane is indicated by + (p<0.05) and a statistically 
significant difference between cells incubated with CP94 and 150 µM dexrazoxane is indicated 
by ∆ (p<0.05).  Times for chelator incubated cells to achieve comparable levels of fluorescence 
to the ALA/MAL/HAL alone treated cells at 6 hr, indicated by the hashed lines on panels (a) – 
(c), are presented in (d). 
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